Erin Duncan
About Erin Duncan
Erin Duncan is the Senior Manager of Quality Operations for Cell Therapy at Bristol Myers Squibb in Switzerland, with extensive experience in GMP auditing and quality assurance across various pharmaceutical companies.
Company
Erin Duncan is currently employed at Bristol Myers Squibb, working as the Senior Manager of Quality Operations in the Cell Therapy division. Bristol Myers Squibb is a renowned global biopharmaceutical company known for its innovative research and development in the field of medicine.
Title
Erin Duncan holds the title of Senior Manager, Quality Operations - Cell Therapy at Bristol Myers Squibb. This role involves overseeing quality operations specifically within the cell therapy sector, ensuring compliance with regulatory standards and maintaining high levels of product quality.
Education and Expertise
Erin Duncan earned a Master of Business Administration (MBA) from the University of Birmingham (2020-2022). She also holds a Master of Science (MSc) in Pharmaceutical Manufacturing Technology from Trinity College, Dublin (2013-2015). In addition, Erin completed a Master of Science (MSc) in Pharmaceutical Quality Assurance and Regulations from Dublin Institute of Technology (2012-2015), and a Bachelor's degree in Pharmacology from the National University of Ireland, Galway (2007-2012).
Background
Erin Duncan has an extensive professional background in the pharmaceutical industry, with roles spanning quality assurance, regulatory compliance, and GMP auditing. She has worked in various positions at companies such as Celgene, Regeneron Pharmaceuticals, Inc., Mylan, and Abbott Diagnostics. Her experience includes roles in development technology, materials and packaging, as well as diagnostic technology.
Achievements
Erin Duncan has held multiple roles focused on GMP compliance at various pharmaceutical companies. She has extensive experience in GMP auditing and quality assurance, and she has been eligible as a Qualified Person (QP) during her tenure at Celgene. Additionally, she has been actively involved in quality operations for cell therapy since 2020, illustrating her specialization and leadership in this advanced pharmaceutical sector.